International Journal of Medical Evaluation and Physical Report E-ISSN 2579-0498
P-ISSN 2695-2181 Vol 9. No. 3 2025 www.iiardjournals.org online version

Investigating the Impact of Antimicrobial Resistance on Global Health and Combating Strategies

Dr. Oyedeji Olugbenga James
University of New Haven, Department of Public Health
Email: hesfa99@gmail.com
DOI: 10.56201/ijmepr.v9.no3.2025.pg90.114

Abstract
The rising threat of antimicrobial resistance (AMR) has prompted the need for alternative approaches to managing antibiotic use in animal production. This study investigates the impact of restrictive antibiotic use in Sweden's animal production sector, focusing on its implications for AMR containment. Using a qualitative approach, the research explores the perspectives of key stakeholders, including farmers, veterinarians, and policymakers, on the feasibility and effectiveness of antibiotic restrictions. In-depth interviews and focus group discussions were conducted to assess the strategies adopted, challenges faced, and the perceived benefits and drawbacks of reduced antibiotic usage in animal husbandry. Findings indicate that while restrictive measures have contributed to a reduction in antibiotic use, they also highlight concerns regarding animal health, productivity, and economic viability. Additionally, stakeholders emphasized the need for more robust surveillance systems, education on alternative management practices, and greater cooperation among various sectors to ensure the sustainable success of antibiotic reduction strategies. This study underscores the importance of balancing antibiotic stewardship with the overall well-being of the animal production system to effectively combat AMR.

Keywords: *Antimicrobial Resistance (AMR), Antibiotic Stewardship, Animal Production, Sweden, Qualitative Study*

1.0 Introduction

Antimicrobial resistance (AMR) refers to the ability of microorganisms—such as bacteria, viruses, fungi, and parasites, to withstand the effects of medications that once effectively treated them. As a result, standard treatments become ineffective, infections persist, and the risk of spread, complications, and death increases. AMR occurs naturally over time, usually through genetic changes, but it is significantly accelerated by human activities such as the overuse and misuse of antibiotics in medicine and agriculture.

The discovery of antibiotics in the early 20th century, particularly penicillin in 1928 by Alexander Fleming, revolutionized the treatment of infectious diseases. However, Fleming himself warned of the potential for resistance if antibiotics were misused. Over the decades, as new antibiotics were developed, bacteria rapidly adapted, resulting in the emergence of resistant strains. The global misuse of antibiotics—through self-medication, incomplete prescriptions, and non-therapeutic use in livestock—has contributed to the widespread evolution of resistance. Today, multidrug-resistant organisms such as *Methicillin-resistant Staphylococcus aureus* (MRSA) and drug-resistant *Mycobacterium tuberculosis* represent growing global health concerns.

AMR is now recognized as one of the most urgent health threats facing humanity. According to the World Health Organization (WHO), AMR is responsible for an estimated 1.27 million deaths annually and contributes to many more. Its impacts are not confined to health alone—it threatens food security, compromises medical advances such as surgeries and chemotherapy, and imposes significant economic burdens on healthcare systems, especially in low- and middle-income countries. The COVID-19 pandemic further exposed the fragility of health systems and the ease with which resistance can escalate in the absence of coordinated action. Despite global efforts, including the WHO's Global Action Plan on AMR, the threat continues to grow, highlighting the need for integrated, cross-sectoral strategies. Antimicrobial resistance (AMR) is increasingly recognized as a pressing global health concern that extends beyond human medicine into sectors such as agriculture, aquaculture, and environmental management. It is estimated that AMR currently contributes to approximately 700,000 deaths annually worldwide, with projections indicating this figure could rise to 10 million by 2050 in the absence of effective intervention (O'Neill, 2016; WHO, 2020). This growing threat calls for a deeper understanding of the complex factors that drive the emergence and cross-border transmission of resistant pathogens.

According to Saxena *et al*. (2025), the burden of AMR is not uniformly distributed across regions. Studies have shown that low- and middle-income countries (LMICs) bear a disproportionate share of the impact due to a combination of environmental contamination, inadequate health infrastructure, limited access to diagnostics, and cultural practices that encourage the misuse of antimicrobials (Karnwal *et al*., 2025Vent). These conditions foster the unchecked spread of resistance and complicate efforts to implement global surveillance and containment strategies.

Historical accounts of AMR trace its origins to the widespread use of antibiotics following the discovery of penicillin, with subsequent decades marked by both the development of new antimicrobial agents and the emergence of resistant strains. The identification of resistance genes and multidrug-resistant organisms—such as MRSA and extended-spectrum β-lactamase-producing bacteria—has further illustrated the evolutionary adaptability of pathogens in response to selective pressures (Brüssow, 2024). These trends underscore the cyclical pattern of drug discovery followed by resistance, often driven by overuse and inappropriate prescribing practices.

Recent literature has also focused on the current landscape of AMR, particularly in high-burden settings such as India. Researchers have emphasized the implications for clinical care, including prolonged hospital stays, treatment failures, and increased healthcare costs. National and global efforts, such as the implementation of antimicrobial stewardship programs, national action plans, and regulations on antibiotic sales, have been explored as strategies to slow the progression of resistance (Chokshi *et al*., 2019). However, the effectiveness of these interventions varies widely depending on political will, public awareness, and infrastructural capacity.

Looking toward the future, researchers have highlighted the need for innovative solutions to tackle AMR. These include the development of novel antimicrobials, the use of bacteriophage therapy, advancements in rapid diagnostic tools, and a One Health approach that integrates human, animal, and environmental health policies. Despite these efforts, several critical gaps remain. There is limited integration of data across sectors, insufficient investment in surveillance infrastructure in LMICs, and a lack of global coordination in research and policy implementation.

Collectively, the literature reveals that while there is a growing body of knowledge on AMR, efforts to combat it are still fragmented and often reactive (Ahmed *et al*., 2024; Ajekiigbe *et al*., 2025; Petersen *et al*., 2024). A more holistic, interdisciplinary approach—supported by sustained political and financial commitment—is essential to address the multifactorial nature of AMR and ensure global health security. This study aims to investigate the multifaceted impact of antimicrobial resistance on global health and to critically evaluate current and emerging strategies for its mitigation. Specifically, it seeks to:

(i) Examine the causes and mechanisms underpinning AMR;
(ii) Analyze the health and economic consequences of AMR on a global scale;
(iii) Review regional trends and disparities in AMR prevalence and response;
(iv) Assess the effectiveness of existing policies, stewardship programs, and innovation efforts;
(v) Recommend comprehensive, sustainable strategies for addressing the AMR crisis.

This research draws on global surveillance reports, peer-reviewed literature, and policy frameworks to provide a holistic view of the AMR landscape. The study covers human health, veterinary practices, environmental factors, and socio-political influences that contribute to resistance development and spread. While several studies have examined individual aspects of AMR, there remains a critical gap in integrative research that bridges scientific, clinical, policy, and societal perspectives to guide holistic action. By addressing this gap, the present study contributes to the body of knowledge needed to inform evidence-based decisions, foster multi-sectoral collaboration, and guide future research and policy interventions. It emphasizes the significance of adopting a One Health approach to mitigate the threat of AMR and ensure the sustainability of global health systems.

2.0 Causes and Mechanisms of Antimicrobial Resistance

Antimicrobial resistance (AMR) is a complex, multifaceted global issue arising from various human, environmental, and microbial factors. The drivers of AMR operate across sectors and regions, necessitating a multidisciplinary and intersectoral understanding. This section examines the primary causes and underlying mechanisms that fuel the development and spread of resistance globally.

2.1 Overuse and Misuse of Antimicrobials in Human Medicine

The inappropriate prescription and use of antibiotics are the most prominent causes of AMR. This includes using antibiotics for viral infections (like colds and flu), incorrect dosages, and failure to complete prescribed treatments.

Empirical studies show a strong correlation between high antibiotic use and resistance levels. For example, **Chokshi *et al*. (2019)** report that up to 50% of antibiotic prescriptions in the United States are either unnecessary or incorrectly dosed. Similarly, **Ahmed *et al*. (2024)** found that self-medication and over-the-counter access to antibiotics in parts of Africa and Asia significantly contribute to resistance.

2.2 Use of Antibiotics in Agriculture and Animal Husbandry

The widespread use of antibiotics in animal agriculture for growth promotion and disease prevention leads to the emergence of resistant bacteria, which can be transmitted to humans through food, water, and direct contact.

O'Neill (2016) estimates that 70% of the world's antibiotics are used in animals. In India and China, studies show resistant *E. coli* and *Salmonella* strains in poultry and livestock, which are identical to those found in human infections (Saxena *et al*., 2025). These findings underline the "One Health" approach needed to address AMR.

2.3 Lack of Infection Prevention and Control

Healthcare facilities lacking proper hygiene, sanitation, and infection control protocols are hotbeds for resistant infections. This is especially true in low-resource settings.

A study by **Ajekiigbe *et al.* (2025)** in Nigerian neonatal intensive care units revealed that inadequate sterilization and overcrowded wards contributed to the spread of multidrug-resistant organisms. In South Asia, **Brüssow (2024)** noted high rates of resistant *Klebsiella pneumoniae* infections in poorly managed hospitals.

2.4 Genetic Mechanisms of Resistance (Mutation, Plasmids, Gene Transfer)

Bacteria acquire resistance through spontaneous mutations or horizontal gene transfer via plasmids, transposons, and integrons. Resistance genes like *blaNDM-1*, *mcr-1*, and *vanA* have become globally distributed due to these mechanisms.

Karnwal *et al*. (2025) highlight how resistance genes can move between species and even genera, enabling pathogens like *Acinetobacter baumannii* and *Pseudomonas aeruginosa* to resist multiple drugs. Molecular epidemiological studies have confirmed plasmid-mediated resistance in hospital and environmental isolates.

2.5 Role of Global Trade and Travel in Spreading AMR

International travel and trade facilitate the global dissemination of resistant pathogens. Tourists, migrants, and imported food products can carry resistant bacteria across borders.

Petersen *et al*. (2024) found that returning travelers from Asia and Africa to Europe often carry resistant strains, even when asymptomatic. WHO (2020) reports that AMR strains like *carbapenem-resistant Enterobacteriaceae* (CRE) have been detected globally within months of their emergence due to interconnected global mobility.

Table 1 presents selected global case studies that exemplify the key causes and mechanisms of antimicrobial resistance (AMR) across various geographical and institutional contexts. The data highlights how overuse in medicine, misuse in agriculture, inadequate infection control, genetic transmission of resistance, and globalization have contributed to the rising prevalence of drug-resistant infections. These cases are drawn from peer-reviewed studies and surveillance reports to offer empirical grounding for the multifaceted nature of AMR.

The case studies underscore the complexity of AMR and the fact that no single factor operates in isolation. For instance, the United States case reflects how inappropriate prescribing behavior in outpatient settings—despite robust healthcare infrastructure—still significantly contributes to resistance (Chokshi *et al*., 2019). This challenges the assumption that AMR is predominantly a problem in low-resource settings.

In contrast, the Indian poultry farming case illustrates the dangers of using antibiotics as growth promoters in food animals, which can lead to direct human health consequences through zoonotic transmission of resistant pathogens like *Salmonella* (Saxena *et al*., 2025). This supports the need for a "One Health" approach that integrates human, animal, and environmental health.

Table 1: Selected Case Studies Demonstrating Causes and Mechanisms of AMR

Case Study Location	AMR Driver	Findings	Reference
United States	Overprescription in outpatient care	50% of prescriptions unnecessary or incorrectly dosed	Chokshi *et al*. (2019)
India	Antibiotic use in poultry farming	Human infections linked to resistant *Salmonella* from poultry	Saxena *et al*. (2025)
Nigeria	Poor hospital hygiene and sanitation	Neonatal sepsis outbreaks caused by multidrug-resistant organisms	Alabi *et al*. (2025), Ajekiigbe *et al*. (2025)
China	Horizontal gene transfer	Discovery of *mcr-1* plasmid in food animals, linked to human infections	Karnwal *et al*. (2025), Li *et al*. (2021)
Europe (travelers)	International travel	Travelers returning from LMICs colonized with resistant bacteria	Petersen *et al*. (2024), Sridher *et al*. (2021)

The Nigerian neonatal unit scenario highlights how institutional factors, particularly weak infection control measures and overcrowding, facilitate the spread of multidrug-resistant organisms in vulnerable populations such as newborns (Ajekiigbe *et al*., 2025). This reflects a broader trend seen in many LMICs, where infrastructural gaps compound the AMR crisis.

From a molecular biology standpoint, the Chinese case involving the *mcr-1* plasmid demonstrates the alarming capacity for resistance genes to spread horizontally across bacterial species and through the food chain, raising the risk of untreatable infections (Karnwal *et al*., 2025). It exemplifies how modern genomics has enabled the tracking of AMR gene flow at a global scale.

Lastly, the European example highlights the impact of international travel and global mobility in spreading resistant bacteria. Tourists and returning migrants often become asymptomatic carriers, unknowingly introducing new resistant strains into local health systems (Petersen *et al*., 2024). This reveals how interconnected the global AMR landscape has become, reinforcing the need for transnational surveillance and cooperative policy-making.

Together, these case studies emphasise that AMR is a globally interconnected problem with locally specific manifestations. Effective strategies must therefore be equally multifaceted, combining local interventions, national policy reforms, and international collaboration. The inclusion of molecular, environmental, social, and clinical data in AMR studies is vital to understanding and curbing its spread.

3.0 Global Health Impact of Antimicrobial Resistance

Antimicrobial resistance (AMR) has emerged as one of the most critical threats to global health, security, and development. Its impacts cut across clinical, economic, and social boundaries, undermining decades of progress in medicine, public health, and sustainable development. As bacteria, viruses, fungi, and parasites become increasingly resistant to treatment, common infections and minor injuries that were once easily curable now pose severe risks. Antimicrobial resistance (AMR) is a growing global health crisis that compromises the effectiveness of standard treatments, leading to prolonged illness and increased mortality. Reports from the World Health

Organization (2023) indicated a high resistance rates in key pathogens including 42% of *E. coli* cases that resisted third-generation cephalosporins, while 35% of *Staphylococcus aureus* strains are methicillin-resistant (MRSA). Additionally, 20% of *E. coli*-related urinary tract infections show reduced susceptibility to common antibiotics. *Klebsiella pneumoniae* is increasingly resistant to high-priority antibiotics, necessitating the use of last-line drugs like carbapenems, which are themselves becoming less effective, especially in low- and middle-income countries. According to projections, resistance to these critical antibiotics could double by 2035 without swift intervention (World Bank, 2017).

Multidrug-resistant fungal pathogens, particularly *Candida auris*, further complicate the AMR landscape due to their resilience against available antifungal agents. AMR also affects major diseases: HIV resistance stems from viral mutations triggered by poor adherence to antiretroviral therapy, while multidrug-resistant tuberculosis (MDR-TB) continues to pose a treatment challenge, with only 40% of patients receiving proper care in 2022. Resistance to artemisinin-based therapies in malaria has emerged in Southeast Asia and parts of Africa, threatening disease control efforts. Similarly, neglected tropical diseases such as leprosy and helminth infections are increasingly resistant to standard drugs, undermining eradication campaigns. In 2019 alone, an estimated 4.95 million deaths were associated with bacterial AMR, including 1.27 million directly attributable deaths—exceeding those from HIV or malaria (Antimicrobial Resistance Collaborators, 2022).

Tackling AMR requires a coordinated One Health approach, integrating human, animal, and environmental health. As of 2023, 178 countries have national AMR action plans, though implementation remains inconsistent. WHO's collaboration with FAO, UNEP, and WOAH through the Quadripartite alliance supports global advocacy, policy development, and political engagement. Initiatives like the AWaRe antibiotic classification system and World AMR Awareness Week (WAAW) promote stewardship and informed antibiotic use. With a fourth high-level ministerial conference slated for 2024 in Saudi Arabia, renewed commitments to AMR containment are anticipated.

3.1 Mortality and Morbidity from Drug-Resistant Infections

AMR significantly contributes to rising mortality and morbidity globally. According to the landmark study by the Global Research on Antimicrobial Resistance (GRAM) project, AMR was directly responsible for 1.27 million deaths in 2019, and associated with 4.95 million deaths globally (Murray *et al*., 2022). These deaths primarily result from sepsis, lower respiratory infections, and intra-abdominal infections. Vulnerable groups such as newborns, cancer patients, and immunocompromised individuals are disproportionately affected due to weakened immune systems and frequent hospitalizations.

3.2 AMR and Healthcare Costs

The economic burden of AMR is substantial. Treatment of drug-resistant infections requires more expensive antibiotics, prolonged hospital stays, isolation wards, and intensive care, all of which drive up healthcare costs. A report by the World Bank (2017) estimated that, if left unchecked, AMR could cause a 3.8% reduction in global GDP by 2050 and push an additional 28 million people into poverty**.** Countries with limited resources face a double burden: higher costs for treatment and weak infrastructure to manage resistance effectively.

3.3 Threat to Modern Medicine and Medical Procedures

AMR threatens the foundation of modern medical procedures that depend on effective antibiotics. Chemotherapy, organ transplants, caesarean sections, and major surgeries all rely on antimicrobial prophylaxis to prevent infection. With rising resistance, these life-saving procedures carry significantly increased risk. For example, infections following surgery that were once rare and manageable are now becoming major contributors to postoperative mortality in some parts of the world (Brüssow, 2024; Carone *et al*., 2024).

3.4 Socioeconomic Burden and Inequities

The burden of AMR is not evenly distributed. Low- and middle-income countries (LMICs) are disproportionately affected due to limited diagnostic capabilities, unregulated antibiotic use, poor sanitation, and overburdened health systems. In rural settings, access to quality antibiotics is limited, while in urban areas, over-the-counter sales without prescription are common. This dual challenge reflects deep inequities in global health systems. Moreover, AMR reduces worker productivity and increases household expenditures, worsening poverty cycles in vulnerable communities (Ahmed *et al*., 2024; Littmann *et al*., 2020).

3.5 Case Studies of Resistant Pathogens

Several high-profile drug-resistant pathogens illustrate the severity of AMR and its impact on public health.

3.5.1 Methicillin-Resistant *Staphylococcus aureus* (MRSA)

MRSA is a major cause of hospital- and community-acquired infections, including skin infections, pneumonia, and bloodstream infections. In the U.S., MRSA infections result in an estimated 19,000 deaths annually (CDC, 2022). The resistance to methicillin and related β-lactams limits therapeutic options and has led to reliance on last-line drugs such as vancomycin. However, in this direction, research is in progress. For example, Kumar *et al*. (2021) examine the growing challenge of antimicrobial resistance (AMR) in *Staphylococcus aureus*, especially methicillin-resistant strains (MRSA), which reduce the effectiveness of common β-lactam antibiotics and necessitate the use of alternatives like vancomycin. The review highlights a concerning slowdown in new antibiotic development, with only two novel classes introduced in the last 20 years. To address these limitations, the authors explore alternative approaches such as bacteriophage therapy, antimicrobial peptides, CRISPR-Cas technologies for targeted bacterial genome editing, monoclonal antibodies against bacterial toxins, and applications of nanomedicine. They also consider the therapeutic potential of plant-based compounds and the repurposing of existing drugs with antimicrobial effects. Their work emphasizes the urgent need for innovative strategies to combat multidrug-resistant *S. aureus* and supports future research into non-traditional treatment pathways.

3.5.2 Multi-Drug Resistant Tuberculosis (MDR-TB)

Multidrug-resistant tuberculosis (MDR-TB) remains a formidable challenge to public health globally, with its impact especially severe in regions such as sub-Saharan Africa, Eastern Europe, and Asia. According to the World Health Organization (WHO, 2023), approximately 450,000 new MDR-TB cases were recorded in 2022 alone. Despite advances in diagnostics and treatment, the success rate for managing MDR-TB remains relatively low, at about 60%, largely due to the toxicity of available drugs, high treatment costs, and prolonged therapy durations. Moreover, the emergence of extensively drug-resistant TB (XDR-TB)—a strain that resists even quinolones and second-line agents—has further complicated control efforts and slowed progress toward global TB eradication.

In response to these challenges, the study by Matteelli and colleagues (2025) offers critical insights into the evolving landscape of MDR-TB prevention. Historically, individuals exposed to MDR-TB—especially within households—were only monitored closely, as no standardized preventive regimen had been approved. However, recent developments, guided by growing ethical concerns and the urgent need to interrupt transmission, have shifted the paradigm. The WHO revised its guidance in 2018 and subsequent years, tentatively endorsing quinolone-based preventive therapy for selected individuals at high risk, although clinical evidence remained sparse.

To fill this gap, two major clinical trials—**VQUIN** and **TB-CHAMP**—were conducted to evaluate whether six months of daily levofloxacin (Lfx) could prevent TB in those who had been in close contact with MDR-TB patients. These randomized, placebo-controlled studies assessed both adult and pediatric populations. When results were pooled through a meta-analysis, the studies showed that individuals who received Lfx had a 60% lower risk of developing active TB compared to those on placebo. This significant finding formed the basis for WHO's 2024 recommendation to implement Lfx as a preventive therapy in MDR-TB contact cases. The regimen demonstrated good tolerability, economic feasibility, and compatibility with HIV treatment, making it suitable for widespread use, especially in low-resource settings.

Despite this progress, a critical issue remains unresolved: the growing threat of pre-XDR and XDR-TB strains that are resistant to fluoroquinolones. As Lfx is ineffective against such strains, alternative therapeutic options are essential. Ongoing studies—including the PHOENIx trial, which is testing delamanid, and the BRANCH-TB trial, exploring a one-month bedaquiline-based regimen—are investigating next-generation options that could provide effective preventive coverage against these more resistant forms of TB.

In summary, the work of Matteelli *et al*. (2025) marks a pivotal advancement in the prevention of MDR-TB, especially through evidence supporting the use of levofloxacin in household contacts. While this represents a significant step toward interrupting TB transmission, the fight against XDR-TB and drug intolerance issues requires continuous research investment. The development of shorter, safer, and more effective prophylactic strategies remains crucial for the eventual eradication of tuberculosis worldwide.

3.5.3 Carbapenem-Resistant Enterobacteriaceae (CRE)

CRE are resistant to nearly all antibiotics, including carbapenems, often considered the last resort. These pathogens cause serious infections such as urinary tract infections, sepsis, and pneumonia in hospitalized patients. Outbreaks in the U.S., India, and Europe have demonstrated CRE's high mortality rate, up to 50% in some cases—and its ability to spread rapidly within healthcare settings (Karnwal *et al*., 2025).

To further illustrate the regional disparities and drivers of antimicrobial resistance (AMR), Table 2 presents a synthesized summary of selected case studies drawn from both developed and developing countries. These cases underscore critical contextual factors—such as unregulated antibiotic access, environmental contamination, and differences in stewardship and policy enforcement, that influence resistance patterns. The table provides a concise comparative perspective that enhances understanding of the global AMR burden and the urgent need for context-specific interventions.

Table 2: Reported cases of Drug-Resistant Pathogens and Their Impact on Global Health

Pathogen	Type of Infection	Region Most Affected	Resistance Mechanism	Health Impact	Source
MRSA	Skin, respiratory, bloodstream infections	USA, UK, India	β-lactamase, PBP2a gene	High mortality, long hospital stays	CDC, 2022; WHO, 2020
MDR-TB	Pulmonary TB	Africa, Asia, Eastern Europe	Resistance to isoniazid and rifampicin	Treatment failure, high cost	WHO, 2023
CRE	UTIs, bloodstream, pneumonia	USA, India, Italy	Carbapenemase enzymes (KPC, NDM)	Up to 50% mortality in ICU	Karnwal *et al.*, 2025
XDR *Salmonella*	Typhoid	Pakistan, Sub-Saharan Africa	Fluoroquinolone and cephalosporin resistance	Outbreaks in children	Saxena *et al.*, 2025
Acinetobacter baumannii	Nosocomial infections	Southeast Asia, Middle East	Efflux pumps, β-lactamases	Highly persistent in hospitals	Ahmed *et al.*, 2024

The global health impact of AMR is multifactorial and severe. It threatens the efficacy of standard medical treatments, exacerbates health inequities, and imposes substantial human and economic costs. Understanding the full scope of AMR's impact—through mortality, financial burden, and resistant pathogens—is critical for driving urgent, coordinated international action.

4.0 Regional and Global Trends in AMR

Antimicrobial resistance (AMR) represents a pressing and escalating global health threat that transcends geographic boundaries. It undermines the efficacy of antimicrobial therapies, exacerbates disease burden, increases healthcare costs, and threatens decades of progress in infectious disease control. Surveillance data, empirical evidence, and field reports indicate that AMR is influenced by a complex interplay of social, environmental, medical, and policy-related factors that vary across regions.

4.1 Overview of Global AMR Surveillance (GLASS, WHO Reports)

The Global Antimicrobial Resistance and Use Surveillance System (GLASS), established by the World Health Organization (WHO) in 2015, is the first standardized global surveillance system for AMR. As of 2023, 127 countries had enrolled in GLASS, with 89 submitting national AMR data (WHO, 2023). The primary function of GLASS is to tracks priority pathogens such as *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Neisseria gonorrhoeae*, and *Salmonella* spp.

According to the 2022 GLASS report, over 50% of *E. coli* isolates were resistant to third-generation cephalosporins in some countries, while resistance to fluoroquinolones and aminoglycosides also increased markedly. Carbapenem-resistant *K. pneumoniae* has been reported from more than 60 countries, with particularly high rates in Asia, Eastern Europe, and parts of Latin America. The WHO emphasizes the need for enhanced laboratory capacity and standardized data reporting in Africa and Southeast Asia, where surveillance systems remain underdeveloped (WHO, 2022). The preliminary findings of a scoping review conducted by Hope *et al*. (2025) provide empirical insights into Africa's progress in implementing the WHO's Global Antimicrobial Resistance Surveillance System (GLASS). The review analyzed 344 studies, of which 38 were included in the final analysis, showing a significant bias toward hospital-based research (95%) and limited sample diversity, with most studies focusing on a single sample type such as blood (46%), urine (32%), or stool (23%). While key pathogens like *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Salmonella*, and *Acinetobacter baumannii* were frequently identified, compliance with GLASS-recommended pathogen-antibiotic combinations was alarmingly low. For instance, only 13% of studies involving *Acinetobacter baumannii* and 9% for *E. coli* adhered to the prescribed testing standards. Notably, none of the studies that recovered pathogens from urine complied with GLASS guidelines. These results highlight a crucial gap in the standardization and comparability of AMR data across African nations, suggesting that while implementation of surveillance is underway, further harmonization and adherence to GLASS protocols are urgently needed to enable actionable insights and effective AMR control strategies.

4.2 AMR Hotspots and Regional Disparities

AMR hotspots are regions characterized by high resistance rates due to a confluence of factors including antibiotic misuse, poor sanitation, unregulated pharmaceutical markets, and limited diagnostic capacity. According to the Global Research on Antimicrobial Resistance (GRAM) project (2022), Sub-Saharan Africa and South Asia had the highest mortality rates attributable to AMR, with over 255,000 and 389,000 deaths respectively in 2019 alone (Murray *et al*., 2022).

Case Study 1: India and Pakistan

Antimicrobial resistance (AMR) remains a growing threat to public health, particularly in countries like India, where the burden is amplified by unregulated antibiotic use across human, veterinary, and environmental sectors. The study by Gunjan *et al*. (2024) provides a comprehensive One Health-based analysis of AMR patterns in India and Germany, revealing alarming trends that necessitate urgent policy and research attention.

The systematic review and meta-analysis included 24 studies from a pool of 532, focusing on AMR prevalence in three compartments: humans, animals, and the environment. In India, the findings indicate a widespread resistance to β-lactam antibiotics in animals, highlighting the extensive misuse of these drugs in livestock for therapeutic and non-therapeutic purposes. In the human sector, quinolone resistance was most prominent, raising concerns about its continued efficacy against common bacterial infections. Environmental compartments, particularly water and soil samples, were reported to harbor aminoglycoside- and β-lactam-resistant bacteria, indicating a spillover from medical and agricultural sources. This aligns with previous concerns that wastewater from hospitals and pharmaceutical industries, along with agricultural runoff, contribute to the persistence of resistant genes in natural ecosystems.

Escherichia coli was identified as the most frequently isolated resistant pathogen across all compartments. Its resistance to β-lactams and cephalosporins, often used as first- or second-line

antibiotics, reflects a critical failure in containment strategies. In India, this resistance pattern is compounded by the widespread misuse and over-the-counter availability of antibiotics.
The review supports earlier findings by Gandra *et al*. (2020), which revealed that carbapenem resistance in *Klebsiella pneumoniae* exceeded 50% in multi-center hospital-based studies across India. This is particularly concerning as carbapenems are considered a last-resort class of antibiotics, and such high resistance significantly narrows treatment options for severe infections. The integrated One Health perspective of the study further emphasizes the need for coordinated AMR surveillance across the human-animal-environment interface. The data clearly demonstrate that AMR is not confined to clinical settings but is deeply entrenched in agriculture and environmental systems. To combat AMR effectively in India, the study advocates for targeted antibiotic stewardship programs, better diagnostic capabilities, and stricter regulations on antibiotic sales and usage. The findings underscore the urgency of implementing national action plans, informed by real-time surveillance data and guided by One Health principles.
Similarly, in Pakistan, widespread availability of antibiotics without prescription has fueled the spread of multidrug-resistant *Acinetobacter baumannii* in tertiary hospitals (Ullah *et al*., 2025).

Case Study 2: Nigeria
In Nigeria, the Nigeria Centre for Disease Control (NCDC) reported high resistance rates in *E. coli* and *Staphylococcus aureus* isolated from bloodstream infections, with over 40% resistance to ciprofloxacin and 35% to gentamicin (NCDC, 2022). The situation is compounded by poor infection control, antibiotic self-medication, and low public awareness.

Case Study 3: Latin America
A review by PAHO (2021) highlighted high resistance to fluoroquinolones and third-generation cephalosporins in *Salmonella* spp. in Mexico and Brazil. The widespread use of antimicrobials in food animals and inadequate waste management are key contributors to environmental contamination with resistant organisms.

Case Study 4: Saudi Arabia
In Saudi Arabia, antimicrobial resistance (AMR) presents a growing public health challenge, marked by rising cases of methicillin-resistant *Staphylococcus aureus* and carbapenem-resistant *Klebsiella pneumoniae* (Matteelli *et al*., 2025; Sheerah *et al*., 2025). The Kingdom's National Action Plan has prioritized improved surveillance, responsible antimicrobial use, and legal restrictions on over-the-counter antibiotic sales. Despite these measures, gaps persist in AMR data collection, particularly in rural areas, limiting nationwide monitoring efforts. Nationwide antibiotic stewardship programs and public awareness campaigns have been implemented, but sustained compliance across human and veterinary sectors remains difficult. Saudi Arabia's leadership in regional AMR control is notable, yet continued success requires strengthening surveillance systems, expanding public education, and enhancing intersectoral collaboration. Given the country's global health relevance, particularly as a pilgrimage hub, Saudi Arabia's efforts are vital to both national and international AMR containment (Sheerah *et al*., 2025).

4.3 AMR in Developing vs. Developed Countries
Disparities in AMR between developing and developed countries are shaped by access to healthcare, regulatory oversight, socioeconomic conditions, and technological capacity. In

developing nations, weak health systems, limited diagnostic tools, and over-the-counter antibiotic sales drive irrational drug use.
According to the World Bank (2017), AMR could cause a reduction of 3.8% in GDP in low-income countries by 2050, pushing an additional 28 million people into poverty. Empirical evidence shows that in low- and middle-income countries (LMICs), 64% of antibiotics are sold without a prescription, compared to less than 10% in high-income countries (Laxminarayan *et al*., 2016b).

Case Study 4: United Kingdom
The UK has implemented strong stewardship policies through the "Start Smart – Then Focus" campaign, resulting in a 17% reduction in antibiotic prescriptions in primary care between 2014 and 2019 (PHE, 2020).

Case Study 5: Kenya
Kenya's National Action Plan (NAP) on AMR has improved reporting of hospital-acquired infections. However, a study by Chuchu *et al*. (2024) showed widespread resistance in community-acquired *E. coli*, with 47% resistant to ciprofloxacin and 23% to ceftriaxone, suggesting that policy efforts are yet to translate into reduced community-level resistance.

4.4 Environmental and Zoonotic Aspects of AMR Spread
Environmental pathways play a pivotal role in AMR propagation. Pharmaceuticals discharged into wastewater, untreated hospital effluents, and animal manure are reservoirs of antibiotic-resistant genes (ARGs). These ARGs can be transferred horizontally to pathogenic bacteria, accelerating resistance.

Case Study 6: Ganges River, India
A study by Larsson & Flach *et al*. (2022) revealed high levels of fluoroquinolone residues and ARGs in the Ganges River near pharmaceutical manufacturing plants. These pollutants contributed to a high concentration of multidrug-resistant bacteria in water samples.

Case Study 7: Poultry Farms in Bangladesh
Research by Jain *et al*. (2021) showed that 76% of *E. coli* isolates from Bangladeshi poultry were resistant to tetracyclines, sulfonamides, and fluoroquinolones. Resistance genes were found both in the animal feces and in the meat sold in markets, raising the risk of transmission to humans.

Case Study 8: Urban Wastewater in South Africa
A study by Oharisi *et al*. (2023) identified a high prevalence of carbapenemase-producing Enterobacteriaceae in untreated urban wastewater in Johannesburg. This suggests that wastewater treatment facilities are critical control points for mitigating environmental AMR spread.

Table 3: Comparative Regional Trends in AMR

Region	Key Resistant Pathogens	Major Drivers	Surveillance Status	Selected Sources
Sub-Saharan Africa	*E. coli*, *K. pneumoniae*, MRSA	OTC antibiotics, weak regulation, poor sanitation	Low surveillance coverage	Murray *et al*. (2022), NCDC (2022)
South Asia	Carbapenem-resistant *K. pneumoniae*, MRSA	Hospital misuse, pharma waste, OTC sales	Moderate, GLASS participation	Gandra *et al*. (2020), WHO (2022)
Latin America	Fluoroquinolone-resistant *Salmonella*, MRSA	Agricultural overuse, weak enforcement	Improving surveillance	PAHO (2021), WHO (2023)
Europe (Eastern)	MDR-TB, VRE, MRSA	Hospital misuse, poor stewardship	High surveillance (EARS-Net)	WHO (2022), PHE (2020)
North America & Western Europe	MRSA, drug-resistant *N. gonorrhoeae*	Antimicrobial overuse in healthcare & livestock	Strong surveillance systems	Laxminarayan *et al*. (2016b), PHE (2020)

The global landscape of AMR is marked by stark regional disparities driven by healthcare system weaknesses, policy lapses, environmental contamination, and socioeconomic inequities. Surveillance systems like GLASS have improved global visibility, but more investments are needed to enhance reporting in low-income settings. The inclusion of environmental and zoonotic dimensions in AMR containment strategies, aligned with the One Health approach, remains critical.

5.0 Strategies for Combating AMR

Efforts to address antimicrobial resistance (AMR) must be multi-pronged, encompassing policy reform, healthcare interventions, scientific innovation, infection prevention, and robust surveillance. These strategies should be guided by evidence-based frameworks and adapted to regional and local contexts. Several empirical studies have demonstrated the effectiveness and limitations of various strategies in combating AMR across different regions.

5.1 Policy and Governance

5.1.1 Implementation of National Action Plans (NAPs)

Many countries have developed National Action Plans (NAPs) aligned with the WHO Global Action Plan to contain AMR. NAPs outline strategic priorities such as strengthening surveillance, optimizing antimicrobial use, enhancing IPC, and raising awareness. For effective implementation, political commitment, intersectoral coordination, and sustainable funding are essential. For example, the United Kingdom's NAP implementation led to a 7.3% reduction in total antibiotic consumption from 2014 to 2018 (Public Health England, 2019). In Kenya, the government has collaborated with the Fleming Fund to build laboratory capacity and improve surveillance infrastructure (Moirongo *et al*., 2022).

5.1.2 WHO Global Action Plan on AMR

The WHO Global Action Plan (2015) provides a strategic blueprint comprising five key objectives: improving awareness, strengthening surveillance, reducing infection incidence, optimizing antimicrobial use, and promoting sustainable investment in new medicines and diagnostics. The plan urges countries to adopt a One Health approach, integrating human, animal, and environmental health strategies. Empirical studies such as those by Laxminarayan *et al*. (2016a) support the effectiveness of the One Health approach in curbing zoonotic AMR transmission.

5.1.3 International Collaboration and Legal Frameworks

Global governance mechanisms such as the Global Leaders Group on AMR, the Tripartite collaboration (WHO, FAO, WOAH), and the United Nations Interagency Coordination Group (IACG) promote coordinated responses to AMR. The European Union's regulation banning prophylactic antibiotic use in livestock (Regulation (EU) 2019/6) is an example of legislative action reducing antimicrobial usage and resistance in the animal sector (EMA, 2020).

5.2 Antibiotic Stewardship Programs

5.2.1 Principles of Stewardship in Hospitals and Clinics

Antibiotic stewardship aims to ensure the right antibiotic is used, at the right dose, for the right duration. Key elements include formulary restrictions, review of empirical therapy, audit and feedback, and clinical guidelines. A systematic review by Baur *et al*. (2017) showed that stewardship programs reduced antibiotic consumption by 19% and improved clinical outcomes.

5.2.2 Role of Healthcare Professionals

Physicians, pharmacists, nurses, and microbiologists play vital roles in stewardship. Their responsibilities include prescribing based on local resistance data, reviewing therapy based on lab results, educating patients, and participating in multidisciplinary stewardship teams. In South Africa, the National Department of Health has implemented hospital-based stewardship committees, which have significantly reduced empirical broad-spectrum antibiotic use (Chetty *et al*., 2019).

5.2.3 Education and Training Initiatives

Education is foundational to stewardship success. Continuous medical education, inclusion of AMR modules in health curricula, and training on IPC protocols help empower healthcare workers. Public awareness campaigns also support behavioral change in antimicrobial use. For instance, the WHO’s World Antibiotic Awareness Week has contributed to increased public knowledge and reduced self-medication in participating countries (WHO, 2021).

5.3 Research and Innovation

5.3.1 Development of New Antibiotics and Antimicrobials

The development of new antibiotics has stagnated due to scientific, regulatory, and economic challenges. Incentivizing research through 'push' (funding) and 'pull' (market entry rewards) mechanisms is crucial. The Global Antibiotic R&D Partnership (GARDP) has supported multiple candidates in late-stage development, including treatments for drug-resistant gonorrhea (GARDP, 2022).

5.3.2 Alternative Therapies (Phage Therapy, Antimicrobial Peptides, CRISPR)

Novel approaches like bacteriophage therapy, antimicrobial peptides, and CRISPR-based gene editing hold promise for targeting resistant pathogens. For instance, a clinical trial in Georgia demonstrated the successful use of phage therapy in treating multidrug-resistant *Acinetobacter baumannii* infections (Schooley *et al*., 2017). While promising, challenges remain regarding regulation, delivery mechanisms, and resistance evolution.

5.3.3 Support for R&D and Public–Private Partnerships

Public–private partnerships (PPPs) such as CARB-X and the Innovative Medicines Initiative (IMI) facilitate drug discovery and diagnostics development by pooling resources and expertise. CARB-X has supported over 80 innovative projects since 2016, including diagnostics and vaccines (Alm & Gallant, 2020).

5.4 Infection Prevention and Control (IPC)

5.4.1 Hand Hygiene and Sanitation

Proper hand hygiene and sanitation are cost-effective IPC measures. WHO's "Five Moments for Hand Hygiene" campaign has been instrumental in reducing healthcare-associated infections (HAIs). A case study from Thailand found that compliance with hand hygiene protocols reduced hospital infections by 45% in one year (Chen *et al*., 2011).

5.4.2 Hospital Infection Control Protocols

Hospitals must implement strict IPC protocols including isolation of infected patients, disinfection of surfaces, screening for resistant organisms, and use of personal protective equipment (PPE). A study in Indian tertiary hospitals reported a significant decline in MRSA transmission following the introduction of comprehensive IPC programs (Gandra *et al*., 2024).

5.4.3 Community-Level Preventive Measures

Vaccination, public health education, safe food handling, and vector control are essential in reducing infection burden at the community level. Preventing infections reduces the need for antibiotics and thus minimizes resistance pressure. In Nigeria, national immunization campaigns have reduced bacterial pneumonia cases, lowering antibiotic prescriptions in children (WHO Nigeria, 2020).

5.5 Surveillance and Data Sharing

5.5.1 Strengthening Laboratory and Diagnostic Capacities

Effective AMR surveillance relies on laboratory capacity to identify resistance patterns. Investment in microbiological infrastructure, staff training, and supply chains is vital, especially in LMICs where diagnostic gaps are significant. The Fleming Fund has supported over 20 countries in Africa and Asia to improve diagnostic labs and reporting systems (Fleming Fund, 2021).

5.5.2 Integrated Surveillance (One Health Approach)

The One Health approach integrates AMR surveillance across human, animal, and environmental health sectors. Platforms like GLASS, along with regional networks such as the Africa CDC AMR surveillance system, help in tracking cross-sectoral trends and identifying emergent threats (Africa CDC, 2022).

5.5.3 Data Collection, Reporting, and Sharing Platforms

Timely data collection and sharing support evidence-based policymaking. Electronic platforms, such as WHONET and regional AMR databases, allow aggregation, visualization, and comparison of resistance trends. Harmonizing data standards ensures interoperability across regions. For instance, the European Antimicrobial Resistance Surveillance Network (EARS-Net) has improved EU-wide data comparability and policymaking (ECDC, 2020).

A comprehensive, coordinated approach incorporating policy, stewardship, innovation, prevention, and surveillance is imperative to tackle AMR. Sustained commitment, adequate resources, and global solidarity are essential to mitigate this evolving threat and preserve antimicrobial efficacy for future generations. As evidenced by case studies across continents, strategic investment, local capacity-building, and international collaboration yield measurable success in the fight against AMR.

6.0 Challenges and Barriers in Tackling AMR

Despite growing global awareness and policy interventions, several persistent challenges hinder effective antimicrobial resistance (AMR) containment. These challenges are particularly acute in low- and middle-income countries (LMICs), where systemic limitations and socio-economic disparities exacerbate the problem.

6.1 Inadequate Funding and Resource Allocation

A critical barrier to AMR control is the lack of sustained funding. Implementing national action plans, strengthening laboratories, conducting surveillance, and promoting research all require considerable investment. However, AMR often competes with other pressing public health priorities.

For example, a 2022 WHO report revealed that fewer than 20% of countries that developed National Action Plans (NAPs) had dedicated budgets for implementation (WHO, 2022). In sub-Saharan Africa, a study by Graham *et al*. (2023) found that many countries rely on donor funding, resulting in fragmented and unsustainable AMR initiatives. The COVID-19 pandemic further diverted resources away from AMR efforts, delaying implementation in several regions.

Case Study: In Nigeria, implementation of its AMR NAP (2017–2022) was hindered by limited domestic funding, with less than 10% of proposed activities fully executed by the end of 2021 due to budgetary shortfalls and lack of inter-agency coordination (FMoH, 2022; Otaigbe & Elikwu, 2023).

6.2 Weak Health Systems and Infrastructure

Robust health infrastructure is a prerequisite for AMR containment, particularly for infection prevention, diagnostics, and stewardship. Many countries struggle with under-resourced health facilities, limited diagnostic laboratories, and poor supply chain systems.

A cross-sectional study conducted in 11 African countries found that fewer than 30% of hospitals had functioning microbiology labs capable of conducting antimicrobial susceptibility testing (ASLM, 2020). Inadequate laboratory capacity results in reliance on empirical prescribing, often leading to inappropriate antibiotic use and resistance development.

Case Study: In rural India, lack of access to microbiological testing meant that 80% of antibiotics were prescribed empirically (Laxminarayan *et al*., 2016a). This practice significantly contributed to the rise of multidrug-resistant organisms in both community and hospital settings.

6.3 Limited Access to Quality Medicines

While some regions face antibiotic overuse, others grapple with limited access to effective and quality-assured antimicrobials. Substandard, falsified, or expired drugs exacerbate resistance by exposing pathogens to sub-therapeutic doses.

According to the WHO Global Surveillance and Monitoring System, 10% of medical products in LMICs are either substandard or falsified, with antimicrobials among the most frequently affected (WHO, 2018). Poor regulatory oversight and weak pharmacovigilance systems further compound this issue.

Empirical Evidence: In a study by Chumia *et al*. (2025), substandard antibiotics were responsible for up to 169,000 pneumonia-related child deaths annually in sub-Saharan Africa and South Asia due to treatment failure and resistance.

6.4 Regulatory and Logistical Challenges

Regulatory weakness is a major barrier, particularly in controlling over-the-counter antibiotic sales and use in agriculture. In many countries, antimicrobials are available without prescription, and their use in livestock is poorly regulated.

For instance, a 2021 study across Southeast Asia revealed that 70% of community pharmacies in Vietnam and 88% in Thailand sold antibiotics without prescription, despite existing regulations (Siltrakool *et al*., 2021). Moreover, the illegal trade of antimicrobials and the absence of harmonized regulations across borders hinder coordinated control efforts.

Case Study: In Brazil, although laws restrict the use of certain antibiotics in animal farming, enforcement remains weak. A 2019 report by ANVISA found residues of banned antibiotics in poultry meat, indicating continued non-compliance in the livestock sector (Rabello *et al*., 2020).

6.5 Societal Attitudes and Behavioral Resistance

Public attitudes and behaviors significantly influence AMR trends. Misconceptions about antibiotics, cultural practices, and lack of awareness lead to misuse and overuse. A survey conducted in 12 European countries found that 57% of respondents incorrectly believed antibiotics were effective against viruses such as the common cold (Eurobarometer, 2018). In LMICs, antibiotics are often viewed as “quick cures,” leading to self-medication and incomplete treatment courses.

Case Study: In Ghana, a community-based study revealed that 47% n of respondents used leftover antibiotics from previous illnesses, while 32% procured antibiotics without prescription from informal vendors (Ngyedu *et al*., 2023). These practices are difficult to reverse without sustained public education and behavior change interventions.

7.0 Future Directions and Recommendations

Addressing the future of antimicrobial resistance (AMR) requires innovative, inclusive, and collaborative strategies that build upon the lessons of past interventions while anticipating emerging global health threats. A central priority is the reinforcement of the One Health approach, which recognizes the interconnectedness of human, animal, and environmental health. Interventions in AMR must therefore extend beyond the healthcare sector to include veterinary practices, agriculture, and environmental monitoring. Integrated surveillance systems such as the WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) and regional programs like TrACSS and InFARM should be expanded to routinely capture data across all sectors. Investments in veterinary microbiology and environmental health research are also critical to ensuring comprehensive AMR detection and response. For example, Thailand implemented cross-sectoral AMR surveillance that facilitated the early identification of colistin resistance, leading to timely regulatory action. Similarly, the Netherlands reduced antibiotic use in livestock by 64% between 2009 and 2018 through a coordinated One Health strategy that linked public health and agricultural policy (Singh *et al*., 2025; Speksnijder *et al*., 2014).

Global equity remains another essential pillar of future AMR responses. Many low- and middle-income countries (LMICs) lack the necessary infrastructure, technology, and financial support to implement effective AMR interventions. It is imperative that international mechanisms provide sustained support to these regions through technology transfer, capacity building, and targeted funding. The Fleming Fund exemplifies such support, having invested over £265 million in 24 LMICs to strengthen laboratory systems, surveillance networks, and data management. In Nepal, this investment led to the creation of a national AMR reference laboratory and integration of data into GLASS, enabling evidence-based national policy formulation (Fleming Fund, 2021). Promoting South–South cooperation and incorporating equity targets into global frameworks, such as the Pandemic Accord and the Sustainable Development Goals (SDG 3), will further ensure that no region is left behind in the global AMR response.

Enhancing policy coherence and fostering multisectoral collaboration is also critical to future AMR control. Many national policies across health, agriculture, trade, and education remain poorly aligned, leading to conflicting objectives and inefficiencies. Governments must therefore integrate AMR into broader national development and economic planning agendas. Regulatory reforms should promote synergy between public health goals and agricultural practices, especially in regulating antibiotic use in animal husbandry. For instance, Sweden successfully reduced antibiotic consumption in livestock without compromising productivity by ensuring close coordination between health and agriculture authorities, and by engaging farmers and consumers in the process (Björkman*et al*., 2021). Effective community participation in policymaking also contributes to policy legitimacy and improves compliance.

The stagnation in the development of new antibiotics continues to pose a formidable barrier in AMR containment. A reimagined incentive framework is required to stimulate research and development while ensuring global access to new antimicrobial products. This includes expanding both ‘push’ mechanisms such as research funding and ‘pull’ mechanisms like market entry rewards. The UK's subscription model offers a promising example, where pharmaceutical companies are paid a fixed annual fee for effective antibiotics regardless of the volume sold. This delinks profit from sales volume and addresses market failure in antibiotic innovation. The model has already been applied to cefiderocol and delafloxacin and has potential for wider adoption (O’Neill Report, 2016). Additionally, nonprofit initiatives like the Global Antibiotic R&D Partnership (GARDP) and public–private platforms such as CARB-X and the Innovative Medicines Initiative (IMI) continue to play essential roles in expanding the antimicrobial pipeline.

Public awareness and engagement must also be scaled up significantly if AMR is to be meaningfully addressed in the long term. Behavioral change at the individual and community level is essential to rational antimicrobial use, but existing awareness efforts remain episodic and poorly localized. Educational content on AMR should be systematically incorporated into school curricula and professional training programs. Mass media and digital campaigns need to be designed with cultural relevance and implemented over sustained periods. Civil society, religious organizations, and social influencers can serve as powerful amplifiers of AMR messaging. The WHO’s World Antimicrobial Awareness Week has played a significant role in elevating global discourse, but grassroots efforts such as India’s "Red Line" campaign—where antibiotics are marked with a red stripe to discourage over-the-counter use—have demonstrated more direct impacts on public behavior.

In summary, the future of AMR mitigation lies in building robust cross-sectoral systems, promoting equity and innovation, ensuring policy integration, and engaging the public at every level. Global solidarity, informed governance, and inclusive health strategies must be at the core of this response to safeguard the efficacy of antimicrobial agents for generations to come.

8.0 Conclusion

The issue of antimicrobial resistance (AMR) has emerged as one of the most significant global health challenges of the 21st century. It is driven by a combination of factors including overuse and misuse of antibiotics, inadequate infection control measures, and insufficient investment in new drug development. The global impact of AMR is profound, threatening to undermine decades of medical progress and complicating the treatment of infectious diseases. This resistance is not only confined to human health but also extends to animals and the environment, underlining the interconnectedness of these domains. The importance of addressing AMR cannot be overstated as the world faces the possibility of a post-antibiotic era where routine surgeries, cancer treatments, and even simple infections could become fatal.

The key findings from the ongoing efforts to combat AMR highlight several important themes. First, while there has been significant progress in raising awareness of AMR globally, the implementation of comprehensive national strategies, such as National Action Plans (NAPs), has been slow, particularly in low- and middle-income countries. The WHO Global Action Plan provides a valuable framework for action, but successful execution requires sustained commitment from governments, healthcare providers, and the private sector. Additionally, the integration of the One Health approach—spanning human, animal, and environmental health—has been identified as a critical strategy, but effective coordination and adequate resources are still lacking in many regions. Antibiotic stewardship programs in healthcare settings have proven effective in reducing inappropriate use, but broader adoption is necessary for substantial impact. The research and development of new antibiotics, while crucial, continues to face barriers related to economic incentives, regulatory challenges, and the rapid pace of resistance evolution.

The urgency of coordinated global action is evident. The AMR crisis does not recognize national borders, and no single country can tackle it alone. As pathogens become resistant to multiple antibiotics, the global community must unite in its response to ensure that effective treatments remain available. The establishment of stronger international frameworks, such as the Global Leaders Group on AMR and the Tripartite collaboration between WHO, FAO, and WOAH, plays a crucial role in aligning efforts. However, international cooperation must go beyond policy alignment to include funding, knowledge sharing, and the joint development of new medical technologies. It is imperative that AMR is integrated into global health priorities, especially in light of the ongoing threats posed by pandemics and emerging diseases.

Finally, sustainable solutions to AMR require a long-term commitment from all sectors of society. From enhancing public awareness and education to encouraging investments in the development of alternative therapies such as phage therapy and antimicrobial peptides, the path forward must be holistic and inclusive. The regulatory and logistical challenges in implementing AMR strategies must be overcome by creating environments conducive to research and collaboration. Moreover, greater equity in access to antibiotics, diagnostics, and healthcare infrastructure is essential to ensuring that all populations are equipped to fight AMR. The focus must be on fostering a global health system that is resilient, adaptive, and capable of addressing the evolving threat of antimicrobial resistance.

As we move forward, it is clear that AMR requires an urgent, multifaceted response. Collective action from governments, healthcare providers, scientists, and the public is essential to curbing the spread of resistant pathogens. The future of antimicrobial effectiveness hinges on our ability to work together, share resources, and prioritize both innovation and prevention. The fight against AMR will require continued vigilance, collaboration, and investment in strategies that ensure we preserve the efficacy of our antimicrobial tools for generations to come.

References

Africa CDC. (2022). Africa CDC Framework for AMR Surveillance.

Ahmed, S. K., Hussein, S., Qurbani, K., Ibrahim, R. H., Fareeq, A., Mahmood, K. A., & Mohamed, M. G. (2024). Antimicrobial resistance: Impacts, challenges, and future prospects. *Journal of Medicine, Surgery, and Public Health, 2,* Article 100081. https://doi.org/10.1016/j.glmedi.2024.100081

Ahmed, S. K., Hussein, S., Qurbani, K., Ibrahim, R. H., Fareeq, A., Mahmood, K. A., & Mohamed, M. G. (2024). Antimicrobial resistance: Impacts, challenges, and future prospects. *Journal of Medicine, Surgery, and Public Health, 2,* Article 100081. https://doi.org/10.1016/j.glmedi.2024.100081

Ajekiigbe, V. O., Ogieuhi, I. J., Odeniyi, T. A., Ogunleke, P. O., Olatunde, J. T., Babalola, A. V., Omoleke, A. A., Omitade, T. F., Olakanmi, D. E., Akingbola, A., & Anthony, C. S. (2025). Understanding Nigeria's antibiotic resistance crisis among neonates and its future implications. *Discover Public Health*, *22*(28). https://doi.org/10.1186/s12982-025-00422-y

Alabi, E. D., Rabiu, A. G., & Adesoji, A. T. (2025, June). A review of antimicrobial resistance challenges in Nigeria: The need for a one health approach. *One Health*, *20*, 101053. https://doi.org/10.1016/j.onehlt.2025.101053

Alm, R. A., & Gallant, K. (2020). Innovation in antimicrobial resistance: The CARB-X perspective. *ACS Infectious Diseases,* *6*(6), 1317–1322. https://doi.org/10.1021/acsinfecdis.0c00026PAHO (2021). Antimicrobial Resistance in the Americas: Report on Surveillance and Trends.

Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: A systematic review and meta-analysis. *The Lancet Infectious Diseases,* *17*(9), 990-1001. https://doi.org/10.1016/S1473-3099(17)30325-0

Björkman, I., Röing, M., Lewerin, S. S., Lundborg, C. S., & Eriksen, J. (2021). Animal production with restrictive use of antibiotics to contain antimicrobial resistance in Sweden—A qualitative study. *Frontiers in Veterinary Science, 7*, 619030. https://doi.org/10.3389/fvets.2020.619030

Brüssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. *Letters in Applied Microbiology, 17*(7), https://doi.org/10.1111/1751-7915.14510

Carone, G., Bonada, M., Belotti, E. G., D'Angeli, E., Piccardi, A., Doniselli, F. M., Gubertini, G., Casali, C., DiMeco, F., & Del Bene, M. (2025). Post-craniotomy infections: A point-by-point approach. *Brain and Spine*, *5*, 104193. https://doi.org/10.1016/j.bas.2025.104193

Centers for Disease Control and Prevention (CDC). (2022). *Antibiotic resistance threats in the United States, 2022*. U.S. Department of Health and Human Services. https://www.cdc.gov/drugresistance/biggest-threats.html

Chen, Y. C., Sheng, W. H., Wang, J. T., Chang, S. C., Lin, H. C., Tien, K. L., Hsu, L. Y., & Tsai, K. S. (2011). Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections. *PLoS One,* *6*(11), e27163. https://doi.org/10.1371/journal.pone.0027163.

Chetty, S., Reddy, M., Ramsamy, Y., Naidoo, A., & Essack, S. (2019). Antimicrobial stewardship in South Africa: A scoping review of the published literature. *JAC-Antimicrobial Resistance*, *1*(3), dlz060. https://doi.org/10.1093/jacamr/dlz060

Chiumia, F. K., Sinjani Muula, A., Chimimba, F., Nyirongo, H. M., Kampira, E., & Khuluza, F. (2025). Substandard antibiotics and their clinical outcomes among hospitalized patients in southern Malawi: A pilot study. *Frontiers in Pharmacology, 16*, 1535501. https://doi.org/10.3389/fphar.2025.1535501

Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019). Global contributors to antibiotic resistance. *Journal of Global Infectious Diseases, 11*(1), 36–42. https://doi.org/10.4103/jgid.jgid_110_18

Chuchu, V. M., Njung'e, J., Muasa, B., Gathira, M., Olela, G., Bubi, K. S., Ashaba, J., Githii, S., Ndanyi, R., Tanui, E., Irungu, J. I., Azegele, A., Kadam, R., & Ferreyra, C. (2024). Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya. *Frontiers in Public Health, 12*, 1411962. https://doi.org/10.3389/fpubh.2024.1411962

ECDC. (2020). Surveillance of antimicrobial resistance in Europe.

EMA. (2020). Sales of veterinary antimicrobial agents in 31 European countries in 2018.

Fleming Fund. (2021). Annual Report.

Gandra, S., Barter, D. M., & Laxminarayan, R. (2020). Economic burden of antibiotic resistance in ESKAPE organisms in India: A retrospective, observational study. *Clinical Infectious Diseases, 72*(1), e42–e48. https://doi.org/10.1093/cid/ciaa008.

Gandra, S., Vasudevan, A. K., Warren, D. K., & Singh, S. K. (2024). Strengthening hospital epidemiology & infection prevention research capacity in India to curb antimicrobial resistance. *Indian Journal of Medical Research, 159*(1), 7–9. https://doi.org/10.4103/ijmr.ijmr_1919_23.

GARDP. (2022). Annual Review.

Graham, C. L. B., Akligoh, H., Ori, J. K., Adzaho, G., Salekwa, L., Campbell, P., Saba, C. K. S., Landrain, T. E., & Santolini, M. (2023). Education-based grant programmes for bottom-up distance learning and project catalysis: Antimicrobial resistance in Sub-Saharan Africa. *Access Microbiology, 5*(3), acmi000472.v3. https://doi.org/10.1099/acmi.0.000472.v3.

Gunjan, G., Pandey, R. P., Himanshu, H., Kaur, K., Ahmad, S., Mukherjee, R., & Chang, C.-M. (2024). Antimicrobial resistance burden in India and Germany in 2022: A systematic analysis along with One Health perspective. *Heliyon, 10*(18), e37910. https://doi.org/10.1016/j.heliyon.2024.e37910

Jain, P., Bepari, A. K., Sen, P. K., Rafe, T., Imtiaz, R., Hossain, M., & Reza, H. M. (2021). High prevalence of multiple antibiotic resistance in clinical *E. coli* isolates from Bangladesh and prediction of molecular resistance determinants using WGS of an XDR isolate. *Scientific Reports, 11*, 22859. https://doi.org/10.1038/s41598-021-02251-w

Karnwal, A., Jassim, A. Y., Mohammed, A. A., Al-Tawaha, A. R. M. S., Selvaraj, M., & Malik, T. (2025). Addressing the global challenge of bacterial drug resistance: Insights, strategies, and future directions. *Frontiers in Microbiology, 16*, Article 1517772. https://doi.org/10.3389/fmicb.2025.1517772

Kumar, S., Mahato, R. P., Ch, S., & Kumbham, S. (2025, March). Current strategies against multidrug-resistant *Staphylococcus aureus* and advances toward future therapy. *The Microbe, 6*, 100281. https://doi.org/10.1016/j.microb.2025.100281

Larsson, D. G. J., & Flach, C. F. (2022). Antibiotic resistance in the environment. *Nature Reviews Microbiology, 20*(5), 257–269. https://doi.org/10.1038/s41579-021-00649-x\

Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: A worldwide challenge. *The Lancet, 387*(10014), 168-175. https://doi.org/10.1016/S0140-6736(15)00474-2

Laxminarayan, R., Sridhar, D., Blaser, M., Wang, M., & Woolhouse, M. (2016a). Achieving global targets for antimicrobial resistance. *Science, 353*(6302), 874–875. https://doi.org/10.1126/science.aaf9286

Li, W., Yan, Y., Chen, J., Sun, R., Wang, Y., Wang, T., Feng, Z., Peng, K., Wang, J., Chen, S., Luo, Y., Li, R., & Yang, B. (2021). Genomic characterization of conjugative plasmids carrying the *mcr-1* gene in foodborne and clinical strains of *Salmonella* and *Escherichia coli*. *Food Control*, *130*, 108032. https://doi.org/10.1016/j.foodcont.2021.108032

Littmann, J., Viens, A. M., & Silva, D. S. (2020). The Super-Wicked Problem of Antimicrobial Resistance. In E. Jamrozik & M. Selgelid (Eds.), *Ethics and Drug Resistance: Collective Responsibility for Global Public Health* (Vol. 5, pp. 443-461). Springer, Cham. https://doi.org/10.1007/978-3-030-27874-8_26

Matteelli, A., Lovatti, S., Rossi, B., & Rossi, L. (2025). Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination. *International Journal of Infectious Diseases*. Advance online publication. https://doi.org/10.1016/j.ijid.2025.107849

Moirongo, R. M., Aglanu, L. M., Lamshöft, M., Adero, B. O., Yator, S., Anyona, S., May, J., Lorenz, E., & Eibach, D. (2022). Laboratory-based surveillance of antimicrobial resistance in regions of Kenya: An assessment of capacities, practices, and barriers by means of multi-facility survey. *Frontiers in Public Health, 10*, 1003178. https://doi.org/10.3389/fpubh.2022.1003178

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Hay, S. I. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet, 399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

NCDC (2022). Antimicrobial Resistance Surveillance Report. Nigeria Centre for Disease Control.

Ngyedu, E. K., Acolatse, J., Akafity, G., Incoom, R., Rauf, A., Seaton, R. A., Sneddon, J., Cameron, E., Watson, M., Wanat, M., Godman, B., & Kurdi, A. (2023). Selling antibiotics without prescriptions among community pharmacies and drug outlets: A simulated client study from Ghana. *Expert Review of Anti-Infective Therapy, 21*(12), 1373–1382. https://doi.org/10.1080/14787210.2023.2283037

Oharisi, O. L., Ncube, S., Nyoni, H., Madikizela, M. L., Olowoyo, O. J., & Maseko, B. R. (2023). Occurrence and prevalence of antibiotics in wastewater treatment plants and effluent receiving rivers in South Africa using UHPLC-MS determination. *Journal of Environmental Management, 345*, 118621. https://doi.org/10.1016/j.jenvman.2023.118621

O'Neill, J. (2016). *Tackling drug-resistant infections globally: Final report and recommendations*. Review on Antimicrobial Resistance. https://amr-review.org

Otaigbe, I. I., & Elikwu, C. J. (2023). Drivers of inappropriate antibiotic use in low- and middle-income countries. *JAC Antimicrobial Resistance, 5*(3), dlad062. https://doi.org/10.1093/jacamr/dlad062

Petersen, E., Lee, S. S., Blumberg, L., & Levison, M. E. (2024). Antimicrobial resistance – A global problem in need of global solutions. *International Journal of Infectious Diseases, 137*, 73–74.

PHE (2020). English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report.

Public Health England. (2019). English Surveillance Programme for Antimicrobial Utilisation and Resistance.

Rabello, R. F., Bonelli, R. R., Penna, B. A., Albuquerque, J. P., Souza, R. M., & Cerqueira, A. M. F. (2020). Antimicrobial Resistance in Farm Animals in Brazil: An Update Overview. *Animals*, *10*(4), 552. https://doi.org/10.3390/ani10040552

Saxena, D., Gwalani, R., Yadav, A., & Shah, R. (2025). Growing concerns on antimicrobial resistance – Past, present, and future trends. *Indian Journal of Community Medicine, 50*(1), 4–8. https://doi.org/10.4103/ijcm.ijcm_838_23

Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., Segall, A. M., Taplitz, R., Smith, D. M., Kerr, K., Kumaraswamy, M., Nizet, V., Lin, L., McCauley, M. D., Strathdee, S. A., Benson, C. A., Pope, R. K., Leroux, B. M., Picel, A. C., Mateczun, A. J., Cilwa, K. E., Regeimbal, J. M., Estrella, L. A., Wolfe, D. M., Henry, M. S., Quinones, J., Salka, S., Bishop-Lilly, K. A., Young, R., & Hamilton, T. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrobial Agents and Chemotherapy*, *61*(10), e00954-17. https://doi.org/10.1128/AAC.00954-17. Erratum in: *Antimicrobial Agents and Chemotherapy, 62*(12), e02221-18. https://doi.org/10.1128/AAC.02221-18WHO (2022). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report.

Sheerah, H. A., Algwizani, A. R., Alghamdi, R. Q., Almohammadi, E. L., Al-Qunaibe, A. M., Dada, H. M., Algarni, H. S., Tunkar, S. M., Altamimi, A. M., Almuzaini, Y. S., & Selbie, D. (2025). Strengthening global health security through antimicrobial resistance control: Insights from Saudi Arabia. *Journal of Infection and Public Health, In Press*. https://doi.org/10.1016/j.jiph.2025.102788.

Siltrakool, B., Berrou, I., Griffiths, D., & Alghamdi, S. (2021). Antibiotics' use in Thailand: Community pharmacists' knowledge, attitudes and practices. *Antibiotics*, *10*(2), 137. https://doi.org/10.3390/antibiotics10020137.

Singh, S., Kriti, M., K.S, A., Sharma, P., Pal, N., Sarma, D. K., Tiwari, R., & Kumar, M. (2025). A one health approach addressing poultry-associated antimicrobial resistance: Human, animal and environmental perspectives. *The Microbe*, *7*, 100309. https://doi.org/10.1016/j.microb.2025.100309

Speksnijder, D., Mevius, D. J., Bruschke, C. J. M., & Wagenaar, J. A. (2014). Reduction of veterinary antimicrobial use in the Netherlands: The Dutch success model. *Zoonoses and Public Health, 62*(s1), 1-8. https://doi.org/10.1111/zph.12167.

Sridhar, S., Turbett, S. E., Harris, J. B., & LaRocque, R. C. (2021, October). Antimicrobial-resistant bacteria in international travelers. *Current Opinion in Infectious Diseases*, *34*(5), 423-431. https://doi.org/10.1097/QCO.0000000000000751

Thabit, A. K., Alabbasi, A. Y., Alnezary, F. S., & Almasoudi, I. A. (2023). An Overview of Antimicrobial Resistance in Saudi Arabia (2013–2023) and the Need for National Surveillance. *Microorganisms*, *11*(8), 2086. https://doi.org/10.3390/microorganisms11082086

Ullah, Z., Ahmad, S., & Mahsood, H. Y. (2025). Antimicrobial resistance (AMR) in Pakistan: A growing crisis. *Gomal Journal of Medical Sciences*, *23*(1), 5–6. https://doi.org/10.46903/gjms/23.1.1897

WHO (2023). WHO Fact Sheet on Antimicrobial Resistance.

WHO Nigeria. (2020). Routine immunization campaigns and child health outcomes.

WHO. (2015). Global Action Plan on Antimicrobial Resistance.

WHO. (2021). Evaluation of World Antibiotic Awareness Week.

World Bank (2017). Drug-resistant infections: A threat to our economic future.

World Bank. (2017). *Drug-resistant infections: A threat to our economic future* (Vol. 2). Washington, DC: International Bank for Reconstruction and Development / World Bank Group. https://documents.worldbank.org/en/publication/documents-reports/documentdetail/323311493396993758

World Health Organization. (2020). *Antimicrobial resistance*. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

World Health Organization. (2020). *Antimicrobial resistance*. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

World Health Organization. (2023). *Global tuberculosis report 2023*. https://www.who.int/publications/i/item/9789240077660